Date: 2014-08-06
Type of information: Licensing agreement
Compound: MVA-based vaccines in Valneva’s EB66® vaccine production cell line
Company: Valneva (France - Austria) Geovax (USA)
Therapeutic area: Infectious diseases
Type agreement: development manufacturing
production
Action mechanism:
Disease: HIV/AIDS
Details: * On October 18, 2011,Vivalis and GeoVax Labs have entered into a biomanufacturing agreement to manufacture GMP-grade materials for the production of GeoVax’s MVAbased vaccines. The Vivalis-GeoVax collaboration, begun in 2008 and supported by a grant from the French innovation agency OSEO, addresses the manufacture of the MVA component of the GeoVax HIV/AIDS vaccine in the VIVALIS EB66® cell line. GeoVax and Vivalis have now entered into a supply agreement to produce master and working cell banks of EB66® cells for GeoVax, a first step leading to the production of clinical trial materials in Vivalis’ GMP facility.
Financial terms: Financial terms of the agreement were not disclosed but do include upfront and annual maintenance payments. If successful the program could lead to a commercial license agreement that includes additional cash payments for achieved milestones with future royalties on net sales.
Latest news: * On August 6, 2014, Valneva announced that it has signed a clinical development license agreement with the US firm GeoVax Labs, Inc. (OTCQB: GOVX), to develop MVAbased vaccines in Valneva’s EB66® vaccine production cell line.
The deal broadens the collaboration between the two companies which have been working together since 2008 to generate a process for manufacturing the MVA component of GeoVax’s HIV/AIDS combination vaccine using Valneva’s EB66® cell line technology. The new agreement will allow GeoVax to enter clinical trials with a candidate vaccine derived from EB66® cells and also permits the transfer of the cell line to a third party GMP manufacturer.
To date, Valneva has more than 35 agreements encompassing over 50 products in development using the EB66® cell line with companies throughout the world.
